1. Home
  2. XPL vs IMMP Comparison

XPL vs IMMP Comparison

Compare XPL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solitario Resources Corp.

XPL

Solitario Resources Corp.

HOLD

Current Price

$0.78

Market Cap

68.1M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.41

Market Cap

61.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPL
IMMP
Founded
1984
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.1M
61.4M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
XPL
IMMP
Price
$0.78
$0.41
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$1.20
$5.50
AVG Volume (30 Days)
72.4K
179.0K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
42.86
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.29
52 Week High
$0.98
$3.53

Technical Indicators

Market Signals
Indicator
XPL
IMMP
Relative Strength Index (RSI) 56.50 53.51
Support Level $0.70 $0.35
Resistance Level $0.79 $0.46
Average True Range (ATR) 0.03 0.03
MACD 0.01 0.00
Stochastic Oscillator 83.61 82.75

Price Performance

Historical Comparison
XPL
IMMP

About XPL Solitario Resources Corp.

Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: